Blue Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$15.1K Sell
61
-163
-73% -$41.5K ﹤0.01% 1593
2026
Q2
$67.4K Sell
224
-42
-16% -$12.7K ﹤0.01% 1216
2026
Q1
$88K Sell
266
-18
-6% -$6.12K ﹤0.01% 1083
2025
Q4
$113K Sell
284
-65
-19% -$28.8K ﹤0.01% 996
2025
Q3
$159K Sell
349
-944
-73% -$384K ﹤0.01% 889
2025
Q2
$422K Buy
1,293
+135
+12% +$37.4K 0.01% 511
2025
Q1
$313K Buy
1,158
+293
+34% +$75.3K ﹤0.01% 553
2024
Q4
$204K Buy
865
+403
+87% +$106K ﹤0.01% 652
2024
Q3
$112K Buy
462
+375
+431% +$97.6K ﹤0.01% 1158
2024
Q2
$13K Buy
87
+72
+480% +$11.4K ﹤0.01% 1833
2024
Q1
$2.24K Sell
15
-27
-64% -$4.5K ﹤0.01% 1803
2023
Q4
$7K Sell
42
-59
-58% -$10K ﹤0.01% 1692
2023
Q3
$19K Buy
101
+10
+11% +$1.91K ﹤0.01% 1191
2023
Q2
$18K Sell
91
-15
-14% -$2.97K ﹤0.01% 1075
2023
Q1
$25K Sell
106
-2
-2% -$420 ﹤0.01% 1282
2022
Q4
$21K Buy
108
+87
+414% +$18.6K ﹤0.01% 1271
2022
Q3
$3K Buy
21
+8
+62% +$1.53K ﹤0.01% 1661
2022
Q2
$2K Buy
+13
New +$1.84K ﹤0.01% 1625

Other funds holding ALNY

Blue Trust's ALNY Position: Q3 2026 in Review

Blue Trust reduced its Alnylam Pharmaceuticals (ALNY) stake by 73% in Q3 2026, selling an estimated $41.5K and leaving 61 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

Blue Trust first reported a position in ALNY in Q2 2022 and has held it in 18 quarters since. The position peaked at $422K in Q2 2025. 633 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Blue Trust held 61 shares of Alnylam Pharmaceuticals worth $15.1K as of Q3 2026.
  • Blue Trust sold 163 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $41.5K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #1593 holding.
  • Blue Trust first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 18 quarters since.
  • Blue Trust's Alnylam Pharmaceuticals position peaked at $422K in Q2 2025.
  • 633 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.